Immuno-Biological Laboratories Co., Ltd.
4570.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥4,470 | ¥4,796 | ¥3,791 | ¥3,046 |
| - Cash | ¥826 | ¥734 | ¥614 | ¥508 |
| + Debt | ¥204 | ¥236 | ¥235 | ¥234 |
| Enterprise Value | ¥3,849 | ¥4,298 | ¥3,411 | ¥2,771 |
| Revenue | ¥970 | ¥817 | ¥795 | ¥648 |
| % Growth | 18.7% | 2.8% | 22.7% | – |
| Gross Profit | ¥628 | ¥517 | ¥527 | ¥377 |
| % Margin | 64.8% | 63.3% | 66.3% | 58.2% |
| EBITDA | ¥227 | ¥128 | -¥332 | -¥250 |
| % Margin | 23.4% | 15.7% | -41.8% | -38.5% |
| Net Income | ¥249 | ¥187 | -¥290 | -¥259 |
| % Margin | 25.7% | 22.9% | -36.5% | -40% |
| EPS Diluted | 26.74 | 20.05 | -31.11 | -27.78 |
| % Growth | 33.4% | 164.4% | -12% | – |
| Operating Cash Flow | ¥183 | ¥134 | ¥26 | -¥93 |
| Capital Expenditures | -¥60 | -¥19 | ¥0 | ¥0 |
| Free Cash Flow | ¥124 | ¥115 | ¥26 | -¥93 |